If You Invested $1,000 in Cormedix (CRMD)
This article analyzes the historical performance of investing $1,000 in Cormedix (CRMD) over one, five, and ten years, comparing its returns against the S&P 500. It details Cormedix's business, focusing on its DefenCath product, its acquisition of Melinta Therapeutics, and its ongoing clinical developments and financial profile. The company is a biopharmaceutical firm specializing in anti-infective therapies, commercializing DefenCath and a portfolio of anti-infective products acquired from Melinta.
CRMD - CorMedix Inc Options
This article provides a comprehensive overview of CorMedix Inc. (CRMD) stock, including its latest close price, performance metrics, financial ratios, and key statistics. It covers insider and institutional ownership, analyst recommendations, and various technical indicators, presenting a detailed snapshot of the company's market position and financial health.
CorMedix Names Elizabeth Hurlburt as Chief Operating, Commercial Officer
CorMedix Inc. (NASDAQ: CRMD) has appointed Elizabeth Hurlburt as its new Chief Operating and Commercial Officer. This strategic hire aims to leverage her extensive experience in product launches and commercial leadership as the company prepares for the potential launch of DefenCath, its lead product. Hurlburt's role is critical in scaling up commercial operations and driving the anticipated success of DefenCath.
[8-K] CorMedix Inc. Reports Material Event
CorMedix Inc. has announced a change in its executive leadership structure, appointing Elizabeth Hurlburt to the new role of Chief Operating and Commercial Officer, expanding her oversight to include all commercial functions, medical affairs, regulatory, and clinical. She will continue reporting to Chairman and CEO Joseph Todisco. As part of this reorganization, Michael Seckler has departed the company, as detailed in the 8-K filing submitted to the SEC.
Liquidity Mapping Around (CRMD) Price Events
The article provides a detailed analysis of Cormedix Inc. (NASDAQ: CRMD) price events, highlighting weak sentiment across all time horizons which supports a short bias. It identifies key resistance and support levels, offering specific entry and target points for long, breakout, and short position trading strategies. The analysis is generated by AI models and includes multi-timeframe signal analysis and risk management parameters.
CRMD,PEP Revenue Breakdown
This article provides detailed
CorMedix (NASDAQ: CRMD) replaces CBIZ with Ernst & Young as auditor
CorMedix Inc. (NASDAQ: CRMD) has appointed Ernst & Young LLP (EY) as its new independent registered public accounting firm for the fiscal year ending December 31, 2026, replacing CBIZ CPAs P.C. The Audit Committee dismissed CBIZ on June 25, 2026. While CBIZ's reports contained no adverse opinions, a previously disclosed material weakness in internal control over financial reporting was noted, concerning the timely review of significant non-routine transactions.
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CorMedix (CRMD) is evolving beyond its initial DefenCath launch, with DefenCath now serving as its primary commercial driver. The acquisition of Melinta has further diversified its anti-infective platform, introducing the longer-term opportunity of Rezzayo. Investors are evaluating the company's growth potential against near-term volatility, considering factors like utilization, reimbursement changes, portfolio integration, and pipeline timing.
CRMD Stock Outlook as DefenCath and Rezzayo Expand Growth Path
CorMedix (CRMD) is transitioning from a narrow launch narrative to a broader growth path driven by DefenCath and the acquisition of Melinta. While DefenCath provides a strong commercial engine and addresses a clear clinical need, the company faces near-term volatility due to reimbursement shifts and integration spending. Rezzayo offers a significant long-term growth opportunity, with a supplemental application expected in late 2026, though the current outlook remains mixed.
Is CRMD Stock a Buy Now After Strong Growth and New Risks?
CorMedix (CRMD) has shown significant growth in 2025 and Q1 2026, driven by DefenCath sales and the acquisition of Melinta. The company possesses sufficient liquidity but faces challenges with DefenCath reimbursement changes, increased competition, and rising operating expenses. While commercial traction is evident, limited earnings visibility and ongoing expenditures make CRMD a "Hold" rather than an aggressive "Buy" according to Zacks Investment Research.
Enterprise value to EBIT forward of CorMedix Inc. – NASDAQ:CRMD
This article presents the enterprise value to EBIT forward for CorMedix Inc. (NASDAQ: CRMD). It appears to be a financial data snippet from TradingView, focusing on key valuation metrics for the biotechnology company. The content primarily shows the name of the company and the specific financial metric.
Price to sales forward of CorMedix Inc. – NASDAQ:CRMD
This article provides financial information for CorMedix Inc. (NASDAQ: CRMD), specifically focusing on its price to sales forward metric. It highlights the company's stock market data and links to various financial tools and services offered by TradingView. The page appears to be a stub or a section of a larger financial data platform.
Is Now The Time To Put CorMedix (NASDAQ:CRMD) On Your Watchlist?
This article analyzes CorMedix (NASDAQ:CRMD) and its potential as an investment by examining its revenue growth, profit margin trends, debt levels, and insider transactions. It highlights the company's significant revenue growth and improving gross profit margins but also points out its current unprofitability and high debt. The article concludes by suggesting that while CorMedix shows promise, potential investors should conduct further due diligence.
Form DEF 14A CorMedix Inc For: 25 June
This article announces the filing of Form DEF 14A by CorMedix Inc. for June 25. It includes a disclaimer about the high risks associated with trading financial instruments and cryptocurrencies, emphasizing that the data provided on the website may not be real-time or accurate. The article also states that Fusion Media will not accept liability for trading losses based on its information.
Enterprise value to EBITDA forward of CorMedix Inc. – NASDAQ:CRMD
This article provides financial information for CorMedix Inc. (NASDAQ: CRMD), specifically focusing on its enterprise value to EBITDA forward. It indicates the stock market and trading status of CRMD.
Form DEF 14A CorMedix Inc For: 25 June By Investing.com
This article announces that CorMedix Inc. has filed Form DEF 14A for June 25. It is a brief corporate filing notification from Investing.com, providing basic details without further analysis.
CorMedix (CRMD) shareholders affirm directors but vote down multiple charter amendments
CorMedix Inc. shareholders affirmed all seven director nominees and approved executive compensation and the 2026 auditor at their annual meeting. However, multiple proposed charter amendments, including those for Certificate of Designation, technical charter changes, class voting on preferred stock, exclusive forum provisions, and expanded officer liability, were not approved. This indicates shareholder support for current leadership but caution regarding changes to the company's governance structure.
Why (CRMD) Price Action Is Critical for Tactical Trading
This article analyzes Cormedix Inc. (CRMD) using AI models, highlighting weak near-term sentiment but strong mid-term indicators within a broader long-term weak bias. It discusses institutional trading strategies, including long, breakout, and short positions, and provides multi-timeframe signal analysis with support and resistance levels. The report emphasizes the critical nature of price action for tactical trading decisions.
Raised 2026 Guidance and DefenCath Momentum Might Change The Case For Investing In CorMedix (CRMD)
CorMedix reported strong Q1 2026 results driven by DefenCath and raised its full-year guidance, emphasizing continued business momentum despite the upcoming expiration of temporary TDAPA reimbursement. The company's investment narrative hinges on DefenCath's sustained performance as a cash engine and the gradual expansion into other hospital anti-infectives like REZZAYO. While the raised guidance reinforces DefenCath's importance, the eventual TDAPA expiration introduces a key uncertainty that investors should consider.
Raised 2026 Guidance and DefenCath Momentum Might Change The Case For Investing In CorMedix (CRMD)
CorMedix reported strong Q1 2026 results driven by DefenCath and raised its full-year guidance, emphasizing continued business momentum despite the upcoming expiration of temporary TDAPA reimbursement. The article suggests that DefenCath remains a crucial revenue driver, while new data for REZZAYO provides a medium-term clinical and regulatory milestone. Investors should carefully consider the impact of the TDAPA expiration and the wide range of fair value estimates for CRMD shares.
CRMD: Raised 2026 Guidance And Late-Stage Pipeline Progress Will Support Undervalued Shares
CorMedix (CRMD) reported Q1 2026 results, showing significant revenue contributions from DefenCath and raising full-year 2026 net revenue guidance to $325 million to $345 million. The company is also progressing with its REZZAYO pipeline, targeting an sNDA submission to the FDA in late 2026 following positive Phase III trial results. Despite a slight downward adjustment in fair value to $15.20, analysts maintain a positive outlook, considering the shares undervalued by 43%.
CorMedix Inc (CRMD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of CorMedix Inc (CRMD), listing major shareholders and their proportional holdings, such as Deep Track Capital LP and BlackRock. It also categorizes shareholders by type and provides institutional shareholding data over several quarters, including changes in shares held and proportion. Additionally, it lists related ETFs with CRMD holdings.
CorMedix Inc (CRMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article from TradingKey provides a revenue breakdown for CorMedix Inc (CRMD), highlighting that relevant data for business segments and profit contribution have not yet been disclosed by the company. It does, however, indicate a significant portion of revenue, totaling $311.71 million, is generated from the United States.
CorMedix Inc (CRMD) Earnings Forecast: Future EPS & Revenue Growth Estimates
CorMedix Inc (CRMD) has an earnings forecast score of 8.29, ranking 44th in the Pharmaceuticals industry, with an average analyst price target of $20.00. Based on 6 analyst ratings, the company generally receives a "Buy" recommendation. The article also provides details on expected revenue and EPS for upcoming quarters.
CorMedix Inc (CRMD) Financial Health: Profitability & Balance Sheet Analysis
CorMedix Inc (CRMD) has a robust financial score of 8.94, ranking 25th out of 157 in the Pharmaceuticals industry, indicating strong financial health and high operating efficiency. The company reported a significant year-over-year revenue increase of 226.05% to $127.43 million and an 86.99% increase in net profit. However, details for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns have not been fully disclosed yet.
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And DefenCath Momentum - Learn Why
CorMedix (CRMD) reported strong Q1 2026 results, with DefenCath driving revenue and management raising guidance for the full year. The company also highlighted progress for REZZAYO, strengthening the investment case despite potential reimbursement pressures for DefenCath after its temporary add-on payment expires. This updated outlook suggests a potential shift in CorMedix's investment narrative, moving towards a stronger long-term growth profile.
CorMedix Inc. (CRMD) Reports Q1 2026 Results
CorMedix Inc. (CRMD) reported strong Q1 2026 results with net revenue of $127.4 million and net income of $38.6 million, driven by DefenCath and the acquired Melinta portfolio. The company raised its 2026 guidance, projecting revenues between $325 million and $345 million and adjusted EBITDA of $115 million-$135 million. CorMedix is preparing for an FDA submission for REZZAYO in H2 2026, aiming for an expanded launch in 2027.
CorMedix (CRMD) holder reports 4.62M shares, 5.89% stake
SHAIBATALHAMD AYMEN ABDALKADER has filed an amended Schedule 13G/A, disclosing beneficial ownership of 4,618,511 shares of CorMedix Inc. (CRMD) common stock, which represents a 5.89% stake in the company. The filing indicates the holder has sole voting and dispositive power over these shares. This amendment, dated June 12, 2026, is the fifth such amendment from this investor.
CorMedix (CRMD): Investor reports 4.62M shares, 5.89% stake
A Schedule 13G/A filing indicates that investor Aymen Abdalkader Shaibata has reported beneficial ownership of 4,618,511 shares of CorMedix Inc. (CRMD) common stock, representing a 5.89% stake. The filing, signed on June 12, 2026, denotes that Shaibata holds sole voting and dispositive power over these shares, signifying a passive investment. This disclosure provides a snapshot of the investor's position but does not detail any recent transactions.
5 Most Profitable Small Cap Stocks to Buy
This article highlights CorMedix Inc. (NASDAQ:CRMD) as one of the most profitable small-cap stocks, detailing its Q1 2026 financial performance, including significant revenue and net income growth driven by DefenCath and the acquired Melinta portfolio. The company has raised its 2026 guidance and is making progress in its late-stage drug development programs, with an FDA submission for REZZAYO planned for the second half of 2026.
5 Most Profitable Small Cap Stocks to Buy
This article highlights CorMedix Inc. (NASDAQ:CRMD) as one of the most profitable small-cap stocks. The company reported strong Q1 2026 results with significant revenue and net income, largely driven by its DefenCath product and the acquired Melinta portfolio. CorMedix also raised its 2026 guidance and is progressing with late-stage programs, including an upcoming FDA submission for REZZAYO.
Federal appeals court upholds CorMedix patent win over Nexus
A federal appeals court has affirmed a lower court ruling in favor of CorMedix Therapeutics, stating that Nexus Pharmaceuticals infringed on patents covering MINOCIN for Injection. This decision prevents Nexus from marketing its generic minocycline product until the patents expire. CorMedix also recently reported strong first-quarter 2026 revenues that surpassed expectations, despite a slight miss on EPS.
Federal appeals court upholds CorMedix patent win over Nexus
A federal appeals court has upheld CorMedix's patent victory against Nexus Pharmaceuticals regarding MINOCIN for Injection, an intravenous minocycline formulation. The ruling affirms a lower court's decision that Nexus infringed on CorMedix's patents and issues a permanent injunction preventing Nexus from marketing its generic product. CorMedix (NASDAQ:CRMD) also reported strong Q1 2026 revenues and maintains an "EXCELLENT" financial health score, with its stock trading below its InvestingPro Fair Value.
Federal appeals court upholds CorMedix patent win over Nexus By Investing.com
A federal appeals court has affirmed CorMedix Therapeutics' patent victory against Nexus Pharmaceuticals regarding MINOCIN for Injection. The ruling upholds a lower court's decision that Nexus infringed on CorMedix's patents, leading to a permanent injunction preventing Nexus from marketing its generic minocycline product. CorMedix also recently reported strong Q1 2026 revenue, surpassing expectations despite a slight EPS miss.
Court blocks generic rival to hospital antibiotic Minocin, backs CorMedix
The U.S. Court of Appeals for the Federal Circuit has affirmed a prior ruling that upholds CorMedix Therapeutics' (Nasdaq: CRMD) patents for MINOCIN® for Injection. The decision also found Nexus Pharmaceuticals' generic minocycline infringing and maintained a permanent injunction, preventing Nexus from marketing its product before CorMedix's patents expire. This strengthens CorMedix's intellectual property position for its hospital antibiotic.
Appeals court upholds CorMedix (NASDAQ: CRMD) MINOCIN® patents and injunction
The U.S. Court of Appeals for the Federal Circuit has affirmed a lower court's judgment that Nexus Pharmaceuticals' generic minocycline product infringes two of CorMedix's MINOCIN® for Injection patents. The court also upheld a permanent injunction preventing Nexus from marketing its generic product before CorMedix's patents expire. This decision strengthens intellectual property protection for CorMedix's intravenous minocycline, used in hospital settings for serious infections.
Can CorMedix Turn Launch Execution Into Momentum?
CorMedix (CRMD) is a specialty pharmaceutical company focused on infection prevention for hemodialysis patients using central venous catheters. The article highlights that its success hinges on effective launch execution, securing reimbursement access, ensuring manufacturing supply, and achieving provider adoption. Key factors for the company going forward include financial flexibility and its ability to navigate the commercial landscape to maintain momentum.
Why Did CRMD Stock Tumble Over 11% Today?
CorMedix Inc.'s (CRMD) stock tumbled over 11% today despite a 312% year-on-year jump in revenue for Q4 2025, reaching $128.6 million largely due to DefenCath sales and the Melinta acquisition. The decline is attributed to an earnings per share (EPS) of $0.16, which significantly missed analysts' estimates of $0.82. Operating expenses also rose by 181% YoY to $48.2 million.
CRMD: Strong growth driven by DefenCath, REZZAYO, and pipeline expansion in institutional markets
CorMedix Therapeutics (CRMD) is a diversified specialty pharma business experiencing strong growth. This growth is attributed to its robust product portfolio, the successful launch of DefenCath, and the expansion of its pipeline, including label extensions for REZZAYO and new opportunities in Total Parenteral Nutrition (TPN) markets. The company's financials are described as strong.
UBS Group AG Sells 454,873 Shares of CorMedix Inc $CRMD
UBS Group AG significantly reduced its stake in CorMedix Inc. by selling 454,873 shares, cutting its holdings by 41.7% in the fourth quarter. Despite this, CorMedix reported strong quarterly earnings, beating analyst estimates with $0.43 EPS and 226.1% year-over-year revenue growth. Analyst sentiment remains positive, with a "Moderate Buy" consensus rating and an average price target of $15.00.
CRMD Q1 earnings beat on DefenCath momentum, guidance raised
CorMedix (CRMD) reported better-than-expected Q1 earnings, driven by strong sales of DefenCath. The company's net product sales reached $8.7 million, surpassing analyst estimates, prompting an upward revision of its full-year 2026 revenue guidance to $33-38 million. This positive performance and outlook reflect the successful commercial launch and growing adoption of DefenCath.
CorMedix: Long-Term Prospects Remain Poor Despite Q1 Beat (NASDAQ:CRMD)
CorMedix remains a "Sell" despite its Q1 outperformance, which is considered unsustainable due to non-recurring revenue and anticipated reimbursement challenges for DefenCath. The company faces an 80% sequential revenue decline for DefenCath post-TDAPA, and management's reaffirmation of 2027 guidance suggests no immediate rebound. Furthermore, delays in the TPN trial and weak Rezzayo data reduce pipeline potential, contributing to a cautious long-term outlook.
HC Wainwright Forecasts CorMedix's Q2 Earnings (NASDAQ:CRMD)
HC Wainwright has increased its Q2 2026 EPS estimate for CorMedix to $0.26 from $0.21, maintaining a "Buy" rating and a $13 price target. This upward revision follows CorMedix's strong Q1 performance, where the company surpassed analyst expectations with $0.43 EPS and a revenue increase of 226.1% year-over-year. Other analysts largely hold a positive view, with a "Moderate Buy" consensus and an average price target of $15 for the stock.
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results
CorMedix (CRMD) reported strong Q1 2026 results with US$127.43 million in revenue and US$38.6 million in net income, leading to a raised full-year 2026 net revenue guidance of US$325 million to US$345 million. This positive financial update, combined with favorable Phase III results for REZZAYO and progress in other pipeline programs, suggests a potential shift in the investment narrative. The company's future hinges on regulatory advancements for REZZAYO and successful navigation of reimbursement landscapes for its core products.
The Bull Case For CorMedix (CRMD) Could Change Following Raised 2026 Guidance And Phase III Results
CorMedix Inc. (CRMD) reported strong first-quarter 2026 results, with revenue of US$127.43 million and net income of US$38.6 million, prompting them to raise their full-year 2026 net revenue guidance to US$325 million to US$345 million. This updated guidance, coupled with positive Phase III results for REZZAYO and progress in other pipeline programs, may significantly alter the investment outlook for the company. Investors are now scrutinizing how these developments could reshape CorMedix's risk-reward profile and future growth trajectory.
CorMedix Inc reports results for the quarter ended March 31 - Earnings Summary
CorMedix Inc has reported its earnings summary for the quarter that concluded on March 31. This brief report, provided by Refinitiv, gives investors and interested parties an overview of the company's financial performance during that period. Additional details may require logging in or creating an account.
CRMD Q1 Earnings Beat on DefenCath Momentum, Guidance Raised
CorMedix (CRMD) reported first-quarter 2026 diluted earnings of 43 cents per share, surpassing the Zacks Consensus Estimate, with net revenue of $127.4 million, significantly exceeding expectations. The strong performance was driven by DefenCath sales and the contribution from the Melinta portfolio acquisition. Following these positive results, management raised its full-year 2026 net revenue and adjusted EBITDA guidance.
Deep Track (CRMD) files Schedule 13G/A reporting 7.94% ownership
Deep Track-affiliated entities have filed a Schedule 13G/A with the SEC, disclosing a 7.94% beneficial ownership in CorMedix Inc. (CRMD), totaling 6,274,076 shares. The filing indicates shared voting and dispositive power among Deep Track Capital, LP, Deep Track Biotechnology Master Fund, Ltd., and David Kroin. This passive investment is based on CorMedix's 79,050,395 outstanding shares as of March 2, 2026.
CorMedix Inc. (NASDAQ:CRMD) Q1 2026 Earnings Call Transcript
CorMedix Inc. reported strong first-quarter 2026 results, with net revenue of $127.4 million and adjusted EBITDA of $70 million, driven by DefenCath utilization and the acquired Melinta portfolio. The company raised its full-year 2026 financial guidance for net revenue to $325 million-$345 million and adjusted EBITDA to $115 million-$135 million, alongside increased DefenCath guidance to $175 million-$195 million. Furthermore, CorMedix announced positive preliminary top-line results from the ReSPECT study for REZZAYO in invasive fungal disease prophylaxis, with plans for an sNDA submission in the second half of 2026.
Cormedix Therapeutics to Participate in two Upcoming Investor Conferences
CorMedix Therapeutics announced its participation in two upcoming investor conferences: the RBC Capital Markets Global Healthcare Conference and the Jefferies Global Healthcare Conference. Management will engage in fireside chats and investor meetings to discuss the company's focus on developing and commercializing therapeutic products for life-threatening conditions in the US. Specific dates and webcast details for both events have been provided.
